NAUT Key Statistics, Chart & Performance
The current stock price of NAUT is 1.95 USD. In the past month the price decreased by -1.52%. In the past year, price increased by 16.77%.
NAUT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.87 | 217.71B | ||
| DHR | DANAHER CORP | 29.69 | 161.70B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 183 | 55.61B | ||
| A | AGILENT TECHNOLOGIES INC | 24.39 | 38.58B | ||
| IQV | IQVIA HOLDINGS INC | 19.38 | 38.39B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.32 | 28.48B | ||
| WAT | WATERS CORP | 29.91 | 22.61B | ||
| ILMN | ILLUMINA INC | 30.08 | 20.04B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.92 | 19.79B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.28 | 15.82B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B | ||
| TEM | TEMPUS AI INC | N/A | 10.51B |
Related stock screener links
About NAUT
Company Profile
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 124 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Company Info
NAUTILUS BIOTECHNOLOGY INC
2701 Eastlake Ave East
Seattle WASHINGTON US
CEO: Adam Stone
Employees: 124
Phone: 12063332001
NAUTILUS BIOTECHNOLOGY INC / NAUT FAQ
What does NAUT do?
Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 124 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
What is the current price of NAUT stock?
The current stock price of NAUT is 1.95 USD. The price increased by 2.09% in the last trading session.
Does NAUTILUS BIOTECHNOLOGY INC pay dividends?
NAUT does not pay a dividend.
How is the ChartMill rating for NAUTILUS BIOTECHNOLOGY INC?
NAUT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for NAUTILUS BIOTECHNOLOGY INC?
NAUTILUS BIOTECHNOLOGY INC (NAUT) operates in the Health Care sector and the Life Sciences Tools & Services industry.
Would investing in NAUTILUS BIOTECHNOLOGY INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NAUT.
How many employees does NAUTILUS BIOTECHNOLOGY INC have?
NAUTILUS BIOTECHNOLOGY INC (NAUT) currently has 124 employees.
NAUT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NAUT. When comparing the yearly performance of all stocks, NAUT is one of the better performing stocks in the market, outperforming 96.02% of all stocks.
NAUT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NAUT. No worries on liquidiy or solvency for NAUT as it has an excellent financial health rating, but there are worries on the profitability.
NAUT Financial Highlights
Over the last trailing twelve months NAUT reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 10.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.26% | ||
| ROE | -37.14% | ||
| Debt/Equity | 0 |
NAUT Forecast & Estimates
8 analysts have analysed NAUT and the average price target is 2.55 USD. This implies a price increase of 30.77% is expected in the next year compared to the current price of 1.95.